Figure 1
K562R and AR230R cells are resistant to imatinib despite inhibition of BCR-ABL1 kinase. (A) Whole cell extracts were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and probed with antibodies directed against ABL1 and phospho-ABL1; α-tubulin was analyzed as a control. (B) Bar graphs represent imatinib IC50 for K562S, K562R, AR230S, and AR230R cells measured by treating these cells with increasing concentrations of imatinib and quantifying cell proliferation by MTS assay after 72 hours. Errors bars represent standard error of the mean (SEM); *P < .05.

K562R and AR230R cells are resistant to imatinib despite inhibition of BCR-ABL1 kinase. (A) Whole cell extracts were resolved by sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-PAGE) and probed with antibodies directed against ABL1 and phospho-ABL1; α-tubulin was analyzed as a control. (B) Bar graphs represent imatinib IC50 for K562S, K562R, AR230S, and AR230R cells measured by treating these cells with increasing concentrations of imatinib and quantifying cell proliferation by MTS assay after 72 hours. Errors bars represent standard error of the mean (SEM); *P < .05.

Close Modal

or Create an Account

Close Modal
Close Modal